All In MedTech

Device Trial Radar · NCT06028919

Power Versus Temperature Controlled Ablation for Treatment of VT

A Randomised Control Trial of Power Versus Temperature-controlled Irrigated Radiofrequency Ablation for the Treatment of Ventricular Tachycardia (VT)

Last checked: Nov 20, 2026Latest source record: Apr 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

61

Actual

Start

Sep 26, 2022

Primary completion

Nov 21, 2025

Study completion Nov 21, 2025

Sponsor

Lead sponsor
University Hospitals Coventry and Warwickshire NHS TrustAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Medtronic; Coventry University
First posted
Sep 8, 2023

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Ventricular Tachycardia (VT) is a life threatening heart rhythm that comes from the bottom chambers of the heart (the ventricles) and is a leading cause of sudden cardiac death. The majority of patients that are at risk of VT or suffer a cardiac arrest will have an Internal Cardiac Defibrillator (ICD) in situ to treat the abnormal heart rhythm. The ICD can deliver a painful shock to restore normal heart rhythm but importantly does not treat the underlying cause. Current treatment for the prevention of recurrent VT include catheter ablation (CA) or medication. Long-term results with global 12 month VT-free survival rates with CA are around 50%. The trial is to compare 2 different types of ablation catheter that are used to cauterise small areas of unhealthy tissue within the heart that are responsible for VT: Diamond Temp (DT) and Tacticath/Tactiflex (TF). Our hypothesis is that the DT ablation catheter will provide comparable efficacy and safety for the treatment of VT as the current industry gold standard (TF).

Conditions

  • Ventricular Tachycardia

Interventions

  • Temperature controlled DiamondTemp (DT) ablation catheterDevice

    The DiamondTemp catheter is a new ablation catheter that uses 6 industrial grade diamonds to actually measure the temperature of the surface tissue being cauterised. This enables the DiamondTemp catheter to control the amount of power being delivered from the ablation catheter into the tissue being ablated by maintaining a constant temperature at the surface of the heart.

  • Tacticath/Tactiflex (TF) ablation catheterDevice

    The Tactiflex ablation catheter is currently the market leader and routinely used for VT ablation.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assessing the efficacy of the DT versus the TF ablation catheter for the treatment of VTTime frame: 12 months post ablation
  2. Assessing the safety of the DT versus the TF ablation catheter for the treatment of VTTime frame: within 30 days or 6 months after index ablation procedure

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • University Hospitals Sussex NHS Foundation Trust

    Brighton, United Kingdom

  • University Hospital Coventry and Warwickshire NHS Trust

    Coventry, West Midlands, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.